5 mikrogram/puff inhalationsspray
Sponsors
Astrazeneca AB, AstraZeneca AB
Conditions
Inadequately Controlled AsthmaSevere and inadequately controlled asthma
Phase 3
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pressurised MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)
CompletedCTIS2023-505787-11-00
Start: 2021-04-29End: 2025-03-18Target: 678Updated: 2025-05-05
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS)
CompletedCTIS2023-505786-88-00
Start: 2021-04-25End: 2025-03-19Target: 441Updated: 2025-03-21
A Randomized, Double-Blind, Parallel Group, Multicenter 24 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler and Open-Label Symbicort® Turbuhaler® in Participants with Inadequately Controlled Asthma (VATHOS)
CompletedCTIS2024-513568-24-00
Start: 2022-03-23End: 2025-02-12Target: 160Updated: 2025-02-20